A Comparison of 2 Modes of Administration of Recombinant Interleukin-2: Continuous Intravenous Infusion Alone Versus Subcutaneous Administration plus Interferon Alpha in Patients with Advanced Renal Cell Carcinoma.

Abstract

Although the introduction of CIV regimens of rIL-2 was a major step forward compared to high-dose bolus, because most patients could be treated in a normal oncology ward, the s/c schedule of rIL-2 + IFN-alpha offers the possibility of outpatient (home) therapy, with no evidence of a reduction in efficacy.